Cyclo Therapeutics (CYTH) Competitors $0.63 +0.01 (+1.61%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CYTH vs. VHAQ, BCAB, CUE, SLS, OSTX, INCR, DBVT, ONCY, BYSI, and VNRXShould you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Viveon Health Acquisition (VHAQ), BioAtla (BCAB), Cue Biopharma (CUE), SELLAS Life Sciences Group (SLS), OS Therapies (OSTX), InterCure (INCR), DBV Technologies (DBVT), Oncolytics Biotech (ONCY), BeyondSpring (BYSI), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry. Cyclo Therapeutics vs. Viveon Health Acquisition BioAtla Cue Biopharma SELLAS Life Sciences Group OS Therapies InterCure DBV Technologies Oncolytics Biotech BeyondSpring VolitionRx Viveon Health Acquisition (NYSE:VHAQ) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Does the MarketBeat Community favor VHAQ or CYTH? Cyclo Therapeutics received 10 more outperform votes than Viveon Health Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformViveon Health AcquisitionN/AN/ACyclo TherapeuticsOutperform Votes1071.43% Underperform Votes428.57% Does the media prefer VHAQ or CYTH? In the previous week, Cyclo Therapeutics had 2 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 2 mentions for Cyclo Therapeutics and 0 mentions for Viveon Health Acquisition. Cyclo Therapeutics' average media sentiment score of 0.45 beat Viveon Health Acquisition's score of 0.00 indicating that Cyclo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Viveon Health Acquisition Neutral Cyclo Therapeutics Neutral Do analysts recommend VHAQ or CYTH? Cyclo Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 50.79%. Given Cyclo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cyclo Therapeutics is more favorable than Viveon Health Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viveon Health Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk and volatility, VHAQ or CYTH? Viveon Health Acquisition has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.46, indicating that its share price is 146% less volatile than the S&P 500. Which has higher valuation & earnings, VHAQ or CYTH? Viveon Health Acquisition has higher earnings, but lower revenue than Cyclo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViveon Health AcquisitionN/AN/A-$610KN/AN/ACyclo Therapeutics$870.73K20.81-$20.06M-$0.90-0.70 Do institutionals & insiders hold more shares of VHAQ or CYTH? 22.1% of Viveon Health Acquisition shares are owned by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are owned by institutional investors. 75.3% of Viveon Health Acquisition shares are owned by insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is VHAQ or CYTH more profitable? Viveon Health Acquisition has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Viveon Health Acquisition's return on equity of 0.00% beat Cyclo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viveon Health AcquisitionN/A N/A N/A Cyclo Therapeutics -2,847.19%-2,741.89%-307.16% SummaryCyclo Therapeutics beats Viveon Health Acquisition on 8 of the 14 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Cyclo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTH vs. The Competition Export to ExcelMetricCyclo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.12M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-0.7046.7391.3417.19Price / Sales20.81411.851,116.59116.80Price / CashN/A182.1042.6437.86Price / Book3.003.894.794.78Net Income-$20.06M-$42.21M$120.07M$225.60M7 Day Performance8.64%-2.14%-1.89%-1.24%1 Month Performance-9.87%4.21%11.45%3.36%1 Year Performance-65.19%18.40%30.61%16.58% Cyclo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTHCyclo Therapeutics3.2044 of 5 stars$0.63+1.6%$0.95+50.8%-62.5%$18.12M$870,725.00-0.709News CoverageVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002BCABBioAtla2.4599 of 5 stars$1.37-5.5%$6.00+338.0%-65.7%$66.23M$11M-0.8560News CoverageGap DownCUECue Biopharma4.6821 of 5 stars$1.04+10.6%$5.00+380.8%-63.1%$65.88M$9.53M-1.1660News CoveragePositive NewsGap UpSLSSELLAS Life Sciences Group0.0103 of 5 stars$0.93+7.1%N/A-27.2%$65.74M$1M-1.3916OSTXOS TherapiesN/A$3.09+2.3%$8.00+158.9%N/A$65.63MN/A0.00N/AGap DownINCRInterCure0.1096 of 5 stars$1.43+8.2%N/A+16.4%$64.94M$272.67M0.00350News CoverageGap UpDBVTDBV Technologies3.5347 of 5 stars$3.13-12.3%$22.50+618.8%-66.8%$64.38M$15.73M-0.73106Gap DownONCYOncolytics Biotech1.9112 of 5 stars$0.82+0.7%$4.00+388.0%-33.0%$63.17MN/A-3.0030News CoverageBYSIBeyondSpringN/A$1.59-3.0%N/A+72.8%$62.06M$1.88M0.0080Positive NewsGap DownVNRXVolitionRx1.7534 of 5 stars$0.67+17.7%$3.75+463.9%+2.4%$61.63M$770,000.00-1.5780Gap Up Related Companies and Tools Related Companies VHAQ Alternatives BCAB Alternatives CUE Alternatives SLS Alternatives OSTX Alternatives INCR Alternatives DBVT Alternatives ONCY Alternatives BYSI Alternatives VNRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYTH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
